TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models

Journal of Experimental Medicine

Volumn 212, Issue 3, 2015, Pages 287-295

  Jay, Taylor R ^a,b   Miller, Crystal M ^a   Cheng, Paul J ^a,b   Graham, Leah C ^c   Bemiller, Shane ^a,e   Broihier, Margaret L ^b   Xu, Guixiang ^a   Margevicius, Daniel ^a   Karlo, J Colleen ^b   Sousa, Gregory L ^c   Cotleur, Anne C ^a   Butovsky, Oleg ^d   Bekris, Lynn ^a   Staugaitis, Susan M ^a   Leverenz, James B ^a   Pimplikar, Sanjay W ^a,b   Landreth, Gary E ^b   Howell, Gareth R ^c   Ransohoff, Richard M ^a   Lamb, Bruce T ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c JACKSON LABORATORY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e KENT STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PEPTIDES AND PROTEINS; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL 2; UNCLASSIFIED DRUG; CD45 ANTIGEN; IMMUNOGLOBULIN RECEPTOR; MAPT PROTEIN, MOUSE; MEMBRANE PROTEIN; TAU PROTEIN; TREM2 PROTEIN, HUMAN; TREM2 PROTEIN, MOUSE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MACROPHAGE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; UPREGULATION; AGE; AGED; ANIMAL; DISEASE MODEL; FEMALE; GENETICS; HIPPOCAMPUS; MALE; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

AGE FACTORS; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIGENS, CD45; DISEASE MODELS, ANIMAL; FEMALE; HIPPOCAMPUS; HUMANS; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MICE, TRANSGENIC; RECEPTORS, IMMUNOLOGIC; TAU PROTEINS; UP-REGULATION;

EID: 84924737031     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20142322     Document Type: Article

References (32)

1. Akiyama, H., S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, N.R. Cooper, P. Eikelenboom, M. Emmerling, B.L. Fiebich, et al. 2000. Inflammation and Alzheimer's disease. Neurobiol. Aging. 21:383-421. http://dx.doi.org/10.1016/S0197-4580(00)00124-X
2. Bird, T.D., R.M. Koerker, B.J. Leaird, B.W. Vlcek, and D.R. Thorning. 1983. Lipomembranous polycystic osteodysplasia (brain, bone, and fat disease): a genetic cause of presenile dementia. Neurology. 33:81-86. http://dx.doi.org/10.1212/WNL.33.1.81
3. Borroni, B., F. Ferrari, D. Galimberti, B. Nacmias, C. Barone, S. Bagnoli, C. Fenoglio, I. Piaceri, S. Archetti, C. Bonvicini, et al. 2014. Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol. Aging. 35:934. e7-934.e10. http://dx.doi.org/10.1016/j.neurobiolaging.2013.09.017
4. Butovsky, O., M.P. Jedrychowski, C.S. Moore, R. Cialic, A.J. Lanser, G. Gabriely, T. Koeglsperger, B. Dake, P.M. Wu, C.E. Doykan, et al. 2014. Identification of a unique TGF-?-dependent molecular and functional signature in microglia. Nat. Neurosci. 17:131-143. http://dx.doi.org/10.1038/nn.3599
5. Cady, J., E.D. Koval, B.A. Benitez, C. Zaidman, J. Jockel-Balsarotti, P. Allred, R.H. Baloh, J. Ravits, E. Simpson, S.H. Appel, et al. 2014. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 71:449-453. http://dx.doi.org/10.1001/jamaneurol.2013.6237
6. Chiu, I.M., E.T. Morimoto, H. Goodarzi, J.T. Liao, S. O'Keeffe, H.P. Phatnani, M. Muratet, M.C. Carroll, S. Levy, S. Tavazoie, et al. 2013. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Reports. 4:385-401. http://dx.doi.org/10.1016/j.celrep.2013.06.018
7. Colonna, M. 2003. TREMs in the immune system and beyond. Nat. Rev. Immunol. 3:445-453. http://dx.doi.org/10.1038/nri1106
8. Cramer, P.E., J.R. Cirrito, D.W. Wesson, C.Y. Lee, J.C. Karlo, A.E. Zinn, B.T. Casali, J.L. Restivo, W.D. Goebel, M.J. James, et al. 2012. ApoE-directed therapeutics rapidly clear ?-amyloid and reverse deficits in AD mouse models. Science. 335:1503-1506. http://dx.doi.org/10.1126/science.1217697
9. Forabosco, P., A. Ramasamy, D. Trabzuni, R. Walker, C. Smith, J. Bras, A.P. Levine, J. Hardy, J.M. Pocock, R. Guerreiro, et al. 2013. Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol. Aging. 34:2699-2714. http://dx.doi.org/10.1016/j.neurobiolaging.2013.05.001
10. Frank, S., G.J. Burbach, M. Bonin, M. Walter, W. Streit, I. Bechmann, and T. Deller. 2008. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia. 56:1438-1447. http://dx.doi.org/10.1002/glia.20710
11. Guerreiro, R., A. Wojtas, J. Bras, M. Carrasquillo, E. Rogaeva, E. Majounie, C. Cruchaga, C. Sassi, J.S. Kauwe, S. Younkin, et al. Alzheimer Genetic Analysis Group. 2013. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368:117-127. http://dx.doi.org/10.1056/NEJMoa1211851
12. Guerreiro, R.J., E. Lohmann, J.M. Brás, J.R. Gibbs, J.D. Rohrer, N. Gurunlian, B. Dursun, B. Bilgic, H. Hanagasi, H. Gurvit, et al. 2013. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 70:78-84. http://dx.doi.org/10.1001/jamaneurol.2013.579
13. Hickman, S.E., N.D. Kingery, T.K. Ohsumi, M.L. Borowsky, L.C. Wang, T.K. Means, and J. El Khoury. 2013. The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci. 16:1896-1905. http://dx.doi.org/10.1038/nn.3554
14. Jiang, T., L. Tan, X.C. Zhu, Q.Q. Zhang, L. Cao, M.S. Tan, L.Z. Gu, H.F. Wang, Z.Z. Ding, Y.D. Zhang, and J.T. Yu. 2014. Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer's disease. Neuropsychopharmacology. 39:2949-2962. http://dx.doi.org/10.1038/npp.2014.164
15. Jonsson, T., H. Stefansson, S. Steinberg, I. Jonsdottir, P.V. Jonsson, J. Snaedal, S. Bjornsson, J. Huttenlocher, A.I. Levey, J.J. Lah, et al. 2013. Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368:107-116. http://dx.doi.org/10.1056/NEJMoa1211103
16. Karch, C.M., and A.M. Goate. 2015. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry. 77:43-51. http://dx.doi.org/10.1016/j.biopsych.2014.05.006
17. Kleinberger, G., Y. Yamanishi, M. Suárez-Calvet, E. Czirr, E. Lohmann, E. Cuyvers, H. Struyfs, N. Pettkus, A. Wenninger-Weinzierl, F. Mazaheri, et al. 2014. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med. 6:243ra86. http://dx.doi.org/10.1126/scitranslmed.3009093
18. Lee, S., G. Xu, T.R. Jay, S. Bhatta, K.W. Kim, S. Jung, G.E. Landreth, R.M. Ransohoff, and B.T. Lamb. 2014. Opposing effects of membraneanchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway. J. Neurosci. 34:12538-12546. http://dx.doi.org/10.1523/JNEUROSCI.0853-14.2014
19. Mildner, A., B. Schlevogt, K. Kierdorf, C. Böttcher, D. Erny, M.P. Kummer, M. Quinn, W. Brück, I. Bechmann, M.T. Heneka, et al. 2011. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J. Neurosci. 31:11159-11171. http://dx.doi.org/10.1523/JNEUROSCI.6209-10.2011
20. Neumann, H., and K. Takahashi. 2007. Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. J. Neuroimmunol. 184:92-99. http://dx.doi.org/10.1016/j.jneuroim.2006.11.032
21. Oakley, H., S.L. Cole, S. Logan, E. Maus, P. Shao, J. Craft, A. Guillozet-Bongaarts, M. Ohno, J. Disterhoft, L. Van Eldik, et al. 2006. Intraneuronal ?-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26:10129- 10140. http://dx.doi.org/10.1523/JNEUROSCI.1202-06.2006
22. Paradowska-Gorycka, A., and M. Jurkowska. 2013. Structure, expression pattern and biological activity of molecular complex TREM-2/DAP12. Hum. Immunol. 74:730-737. http://dx.doi.org/10.1016/j.humimm.2013.02.003
23. Prinz, M., and J. Priller. 2014. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat. Rev. Neurosci. 15:300-312. http://dx.doi.org/10.1038/nrn3722
24. Radde, R., T. Bolmont, S.A. Kaeser, J. Coomaraswamy, D. Lindau, L. Stoltze, M.E. Calhoun, F. Jäggi, H. Wolburg, S. Gengler, et al. 2006. A?42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7:940-946. http://dx.doi.org/10.1038/sj.embor.7400784
25. Rayaprolu, S., B. Mullen, M. Baker, T. Lynch, E. Finger, W.W. Seeley, K.J. Hatanpaa, C. Lomen-Hoerth, A. Kertesz, E.H. Bigio, et al. 2013. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol. Neurodegener. 8:19. http://dx.doi.org/10.1186/1750-1326-8-19
26. Riddell, D.R., H. Zhou, T.A. Comery, E. Kouranova, C.F. Lo, H.K. Warwick, R.H. Ring, Y. Kirksey, S. Aschmies, J. Xu, et al. 2007. The LXR agonist TO901317 selectively lowers hippocampal A?42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 34:621-628. http://dx.doi.org/10.1016/j.mcn.2007.01.011
27. Sedgwick, J.D., S. Schwender, H. Imrich, R. Dörries, G.W. Butcher, and V. ter Meulen. 1991. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc. Natl. Acad. Sci. USA. 88:7438-7442. http://dx.doi.org/10.1073/pnas.88.16.7438
28. Sharif, O., R. Gawish, J.M. Warszawska, R. Martins, K. Lakovits, A. Hladik, B. Doninger, J. Brunner, A. Korosec, R.E. Schwarzenbacher, et al. 2014. The triggering receptor expressed on myeloid cells 2 inhibits complement component 1q effector mechanisms and exerts detrimental effects during pneumococcal pneumonia. PLoS Pathog. 10:e1004167. http://dx.doi.org/10.1371/journal.ppat.1004167
29. Sieber, M.W., N. Jaenisch, M. Brehm, M. Guenther, B. Linnartz-Gerlach, H. Neumann, O.W. Witte, and C. Frahm. 2013. Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke. PLoS ONE. 8:e52982. http://dx.doi.org/10.1371/journal.pone.0052982
30. Ulrich, J.D., M.B. Finn, Y. Wang, A. Shen, T.E. Mahan, H. Jiang, F.R. Stewart, L. Piccio, M. Colonna, and D.M. Holtzman. 2014. Altered microglial response to A? plaques in APPPS1-21 mice heterozygous for TREM2. Mol. Neurodegener. 9:20. http://dx.doi.org/10.1186/1750-1326-9-20
31. Wyss-Coray, T. 2006. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12:1005-1015.
32. Zhang, B., C. Gaiteri, L.G. Bodea, Z. Wang, J. McElwee, A.A. Podtelezhnikov, C. Zhang, T. Xie, L. Tran, R. Dobrin, et al. 2013. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell. 153:707-720. http://dx.doi.org/10.1016/j.cell.2013.03.030.